Immuron (ASX:IMC) recorded a 13% quarterly increase in the global sales of its immune supplement, Travelan, in the September quarter, according to a Tuesday filing with the Australian bourse.

Sales of Travelan in Australia increased 3% to AU$1 million in the September quarter from AU$983,000 in the three months to June. North American sales climbed 48% to AU$456,000 from AU$309,000 in the June quarter.

The biopharmaceutical company's shares were up nearly 4% in recent Tuesday trade.

Price (AUD): $0.09, Change: $+0.003, Percent Change: +3.66%